Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Joshua Spector maintains Ashland (NYSE:ASH) with a Buy and lowers the price target from $116 to $107.
BMO Capital analyst John McNulty maintains Ashland (NYSE:ASH) with a Market Perform and lowers the price target from $105 to...
Wells Fargo analyst Michael Sison maintains Ashland (NYSE:ASH) with a Overweight and lowers the price target from $112 to $100.
JP Morgan analyst Jeffrey Zekauskas upgrades Ashland (NYSE:ASH) from Underweight to Neutral and lowers the price target from...
Ashland To Sell Nutraceuticals Business To Turnspire Capital Planning For Choppy Demand Environment While Advancing Long-Term G...
Ashland (NYSE:ASH) reported quarterly earnings of $1.49 per share which beat the analyst consensus estimate of $1.45 by 2.76 pe...
BMO Capital analyst John McNulty maintains Ashland (NYSE:ASH) with a Market Perform and raises the price target from $97 to ...
